These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 18073475)
1. Prognostic value of natriuretic peptides in Chagas' disease: a 3-year follow-up investigation. Moreira Mda C; Heringer-Walther S; Wessel N; Moreira Ventura T; Wang Y; Schultheiss HP; Walther T Cardiology; 2008; 110(4):217-25. PubMed ID: 18073475 [TBL] [Abstract][Full Text] [Related]
2. Does the C-type natriuretic peptide have prognostic value in chagas disease and other dilated cardiomyopathies? Heringer-Walther S; Moreira Mda C; Wessel N; Wang Y; Ventura TM; Schultheiss HP; Walther T J Cardiovasc Pharmacol; 2006 Dec; 48(6):293-8. PubMed ID: 17204908 [TBL] [Abstract][Full Text] [Related]
3. Prognostic value of natriuretic peptides in Chagas' disease: a head-to-head comparison of the 3 natriuretic peptides. Moreira Mda C; Wang Y; Heringer-Walther S; Wessel N; Walther T Congest Heart Fail; 2009; 15(2):75-81. PubMed ID: 19379453 [TBL] [Abstract][Full Text] [Related]
4. Plasma ACE2 activity is an independent prognostic marker in Chagas' disease and equally potent as BNP. Wang Y; Moreira Mda C; Heringer-Walther S; Ebermann L; Schultheiss HP; Wessel N; Siems WE; Walther T J Card Fail; 2010 Feb; 16(2):157-63. PubMed ID: 20142028 [TBL] [Abstract][Full Text] [Related]
5. Usefulness of natriuretic Peptide levels to predict mortality in adults with congenital heart disease. Giannakoulas G; Dimopoulos K; Bolger AP; Tay EL; Inuzuka R; Bedard E; Davos C; Swan L; Gatzoulis MA Am J Cardiol; 2010 Mar; 105(6):869-73. PubMed ID: 20211335 [TBL] [Abstract][Full Text] [Related]
6. Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. Selvais PL; Robert A; Ahn S; van Linden F; Ketelslegers JM; Pouleur H; Rousseau MF J Card Fail; 2000 Sep; 6(3):201-7. PubMed ID: 10997745 [TBL] [Abstract][Full Text] [Related]
7. Effects of exercise testing on natriuretic peptide secretion in patients with atrial fibrillation. Wozakowska-Kapłon B; Opolski G Kardiol Pol; 2009 Mar; 67(3):254-61. PubMed ID: 19378231 [TBL] [Abstract][Full Text] [Related]
8. Amino-terminal fragment of C-type natriuretic peptide precursor and C-type natriuretic peptide do not correlate in patients with Chagas disease: role for neutral endopeptidase. Wang Y; Moreira Mda C; Heringer-Walther S; Schultheiss HP; Siems WE; Wessel N; Walther T J Cardiovasc Pharmacol; 2010 Jan; 55(1):62-6. PubMed ID: 20090473 [TBL] [Abstract][Full Text] [Related]
9. How often we need to measure brain natriuretic peptide (BNP) blood levels in patients admitted to the hospital for acute severe heart failure? Role of serial measurements to improve short-term prognostic stratification. Faggiano P; Valle R; Aspromonte N; D'Aloia A; Di Tano G; Barro S; Giovinazzo P; Milani L; Lorusso R; Dei Cas L Int J Cardiol; 2010 Apr; 140(1):88-94. PubMed ID: 19321212 [TBL] [Abstract][Full Text] [Related]
10. Natriuretic peptides in patients with atrial fibrillation. Wozakowska-Kapłon B; Opolski G; Herman Z; Kosior D Cardiol J; 2008; 15(6):525-9. PubMed ID: 19039756 [TBL] [Abstract][Full Text] [Related]
11. Natriuretic peptides as markers of preclinical cardiac disease in obesity. Grandi AM; Laurita E; Selva E; Piantanida E; Imperiale D; Giovanella L; Guasti L; Venco A Eur J Clin Invest; 2004 May; 34(5):342-8. PubMed ID: 15147331 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Mark PB; Stewart GA; Gansevoort RT; Petrie CJ; McDonagh TA; Dargie HJ; Rodger RS; Jardine AG Nephrol Dial Transplant; 2006 Feb; 21(2):402-10. PubMed ID: 16221702 [TBL] [Abstract][Full Text] [Related]
13. Natriuretic peptide response to dynamic exercise in patients with atrial fibrillation. Engelmann MD; Niemann L; Kanstrup IL; Skagen K; Godtfredsen J Int J Cardiol; 2005 Oct; 105(1):31-9. PubMed ID: 16207542 [TBL] [Abstract][Full Text] [Related]
14. Effects of immunoadsorption on the nt-BNP and nt-ANP plasma levels of patients suffering from dilated cardiomyopathy. Staudt A; Staudt Y; Hummel A; Empen K; Dörr M; Trimpert C; Birkenmeier K; Kühl U; Noutsias M; Russ D; Felix SB Ther Apher Dial; 2006 Feb; 10(1):42-8. PubMed ID: 16556135 [TBL] [Abstract][Full Text] [Related]
16. Prognostic value of increased plasma levels of brain natriuretic peptide in patients with septic shock. Ueda S; Nishio K; Akai Y; Fukushima H; Ueyama T; Kawai Y; Masui K; Yoshioka A; Okuchi K Shock; 2006 Aug; 26(2):134-9. PubMed ID: 16878020 [TBL] [Abstract][Full Text] [Related]
17. [The examination of clinical prognostic importance of atrial and brain natriuretic peptide in patients with acute myocardial infarction]. Mazurek W; Salomon P Pol Merkur Lekarski; 2002 Jan; 12(67):15-9. PubMed ID: 11957795 [TBL] [Abstract][Full Text] [Related]
18. Neurohormonal risk stratification for sudden death and death owing to progressive heart failure in chronic heart failure. Berger R; Huelsmann M; Strecker K; Moertl D; Moser P; Bojic A; Pacher R Eur J Clin Invest; 2005 Jan; 35(1):24-31. PubMed ID: 15638816 [TBL] [Abstract][Full Text] [Related]
19. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981 [TBL] [Abstract][Full Text] [Related]
20. Atrial and brain natriuretic peptides as markers of cardiac load and volume retention in primary aldosteronism. Kato J; Etoh T; Kitamura K; Eto T Am J Hypertens; 2005 Mar; 18(3):354-7. PubMed ID: 15797653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]